Journal Mobile Options
Table of Contents
Vol. 31, No. 1-3, 2011
Issue release date: January 2011
Blood Purif 2011;31:189–196
(DOI:10.1159/000321845)

Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease

Vaziri N.D.a · Norris K.b
aDivision of Nephrology and Hypertension, University of California Irvine, Irvine, Calif., and bDepartment of Internal Medicine, Charles Drew University, Los Angeles, Calif., USA
email Corresponding Author

Abstract

Cardiovascular disease is the major cause of death in patients with chronic kidney disease (CKD). Cardiovascular disease and many other complications of CKD are mediated by oxidative stress, inflammation, and dyslipidemia. This review provides a concise overview of the nature and mechanisms of CKD-induced lipid disorders and their adverse consequences. Lipid abnormalities in end-stage renal disease are characterized by: (a) reduced serum apoA-1 and high-density lipoprotein (HDL) concentrations, impaired HDL maturation and defective HDL antioxidant, anti-inflammatory and reverse cholesterol transport properties; (b) impaired clearance of very low-density lipoprotein and chylomicrons by the muscle and adipose tissue and of their remnants by the liver leading to hypertriglyceridemia, accumulation of intermediate-density lipoprotein and chylomicron remnants, and (c) oxidative modification of LDL and lipoprotein remnants favored by their structural abnormalities, oxidative stress, and impaired HDL antioxidant activity. Together these abnormalities result in: (a) uptake of oxidized LDL and remnant particles by macrophages and resident cells in the artery wall which along with impaired HDL-mediated reverse cholesterol transport causes foam cell formation and atherosclerosis, (b) production of inflammatory mediators and reactive oxygen species by leukocytes and macrophages in response to stimulation by oxidized LDL and phospholipids leading to intensification of oxidative stress and inflammation, (c) dissemination of oxidative stress by circulating oxidized lipids and lipoproteins via lipid peroxidation chain reaction, (d) heightened injurious effects of oxidative stress and inflammation due to diminished antioxidant, anti-inflammatory and antithrombotic activities of HDL, and finally (e) impaired ability of very low-density lipoprotein and chylomicron to deliver lipid fuel to muscle and adipose tissue contributing to muscle weakness and cachexia which commonly occur in end-stage renal disease patients.


 Outline


 goto top of outline Key Words

  • End-stage renal disease
  • Atherosclerosis
  • Cardiovascular disease
  • High-density lipoprotein
  • Cholesterol
  • Triglycerides
  • Cachexia
  • Impaired exercise capacity

 goto top of outline Abstract

Cardiovascular disease is the major cause of death in patients with chronic kidney disease (CKD). Cardiovascular disease and many other complications of CKD are mediated by oxidative stress, inflammation, and dyslipidemia. This review provides a concise overview of the nature and mechanisms of CKD-induced lipid disorders and their adverse consequences. Lipid abnormalities in end-stage renal disease are characterized by: (a) reduced serum apoA-1 and high-density lipoprotein (HDL) concentrations, impaired HDL maturation and defective HDL antioxidant, anti-inflammatory and reverse cholesterol transport properties; (b) impaired clearance of very low-density lipoprotein and chylomicrons by the muscle and adipose tissue and of their remnants by the liver leading to hypertriglyceridemia, accumulation of intermediate-density lipoprotein and chylomicron remnants, and (c) oxidative modification of LDL and lipoprotein remnants favored by their structural abnormalities, oxidative stress, and impaired HDL antioxidant activity. Together these abnormalities result in: (a) uptake of oxidized LDL and remnant particles by macrophages and resident cells in the artery wall which along with impaired HDL-mediated reverse cholesterol transport causes foam cell formation and atherosclerosis, (b) production of inflammatory mediators and reactive oxygen species by leukocytes and macrophages in response to stimulation by oxidized LDL and phospholipids leading to intensification of oxidative stress and inflammation, (c) dissemination of oxidative stress by circulating oxidized lipids and lipoproteins via lipid peroxidation chain reaction, (d) heightened injurious effects of oxidative stress and inflammation due to diminished antioxidant, anti-inflammatory and antithrombotic activities of HDL, and finally (e) impaired ability of very low-density lipoprotein and chylomicron to deliver lipid fuel to muscle and adipose tissue contributing to muscle weakness and cachexia which commonly occur in end-stage renal disease patients.

Copyright © 2011 S. Karger AG, Basel


goto top of outline Introduction

Accelerated atherosclerosis and cardiovascular disease are the main cause of death in patients with chronic kidney disease (CKD) [1]. Atherosclerosis and cardiovascular disease as well as many other complication of CKD are primarily driven by oxidative stress, inflammation, and lipid disorders [2,3,4,5,6,7,8]. This review is intended to provide a concise overview of the CKD-associated disorders of lipid metabolism and their contribution to the pathogenesis of atherosclerosis, inflammation, oxidative stress, impaired exercise capacity and wasting syndrome.

 

goto top of outline Effects of CKD on Lipid Profile

The plasma lipid profile frequently evolves during the course of progression of CKD. For instance, patients with mild to moderate CKD, especially those with significant proteinuria, commonly exhibit hypercholesterolemia and elevated low-density lipoprotein (LDL) levels [7]. However, serum total cholesterol and LDL cholesterol concentrations are usually normal or reduced in patients with end-stage renal disease (ESRD) maintained on hemodialysis. Serum triglycerides and very low-density lipoprotein (VLDL) levels are elevated, and clearance of VLDL and chylomicrons and their atherogenic remnants is impaired in patients with advanced CKD or ESRD. This is accompanied by presence of small dense LDL and accumulation of oxidized LDL, intermediate-density lipoprotein (IDL) and chylomicron remnants [7,8,9,10]. The other major CKD-induced lipid disorder is significant reduction in serum apoA-1 and high-density lipoprotein (HDL) cholesterol concentration, impaired HDL maturation and defective HDL antioxidant, anti-inflammatory and reverse cholesterol transport (RCT) capacities [7,8,11,12,13].

In ESRD patients, the dialysis modality can significantly affect lipid profile. For instance, unlike hemodialysis patients, peritoneal dialysis patients frequently have elevated serum total cholesterol and LDL cholesterol levels simulating the lipid profile seen in nephrotic syndrome [7,9,10]. This phenomenon appears to be due to the losses of proteins in the peritoneal fluid effluent mimicking heavy proteinuria in functionally anephric person [14,15].

In addition to dialysis modality, plasma lipid profile can be influenced by concomitant genetic disorders of lipid metabolism, severity of inflammation, malnutrition and lipid-altering drugs such as statins, fibrates, steroids, rapamycin, calcineurin inhibitors and sevelamer among others. In this context, binding and sequestration of bile acids by the phosphate-binding resin sevelamer can significantly reduce serum cholesterol level.

The prevailing oxidative stress and inflammation which are constant feature of CKD [2,3] result in activation of endothelial cells, upregulation of adhesion molecules, expression of chemotactic factors leading to adhesion and infiltration of monocytes and their transformation to macrophages in the artery wall [16]. Simultaneously oxidative stress promotes oxidation of LDL, remnant particles and phospholipids and their uptake by macrophages in the artery wall. This, in turn, results in formation of foam cells, which is a critical step in development and progression of atherosclerosis. The underlying mechanisms responsible for the CKD-induced lipid disorders are briefly described below.

 

goto top of outline HDL Metabolism and Function in CKD

goto top of outline Physiologic Functions of HDL

As illustrated in figure 1, normal HDL protects against atherosclerosis by several mechanisms [17,18,19]: (a) inhibition and reversal of lipid and lipoprotein oxidation via HDL’s constituent antioxidant enzymes paraoxonase and glutathione peroxidase; (b) removal and disposal of oxidized fatty acids via apoA1 and lecithin:cholesterol acyltransferase (LCAT); (c) suppression of inflammation via uptake and disposal of endotoxin and oxidized phospholipids by apoA1 and conversion of ox-LDL by paraoxonase; (d) retrieval of surplus cholesterol and phospholipids from vascular and other tissues for disposal in the liver, a phenomenon which is commonly known as RCT; (e) antithrombotic action via platelet-activating factor acetylhydrolase, which is a potent platelet inhibitor; (f) contribution to metabolism of VLDL and chylomicrons and limiting formation of their atherogenic remnants by donating ApoC and ApoE to the nascent chylomicrons and VLDL, a process which is essential for metabolism and clearance of these lipoproteins [20], and (g) contribution to cholesterol enrichment and triglyceride depletion of IDL and its maturation to LDL via cholesteryl ester transfer protein (CETP)-mediated exchange of cholesterol ester for triglycerides. This process is referred to as indirect RCT as it employs LDL to dispose a portion of HDL’s cholesterol cargo in the liver via LDL receptor. This phenomenon is important in conversion of oxidation-prone atherogenic IDL to cholesterol-rich LDL which can be readily removed by the liver. Iatrogenic disruption of this process may have been responsible for paradoxical increase in adverse cardiovascular outcomes despite dramatic rise in HDL cholesterol which resulted in early termination of clinical trials of a CETP inhibitor [21].

FIG01
Fig. 1. Role of HDL in reverse cholesterol pathway. In the presence of oxidative stress, reactive oxygen species (ROS) oxidize LDL and remnant lipoproteins. HDL mitigates this process via its antioxidant enzyme constituents, paraoxonase-1 (PON-1) and glutathione peroxidase (GPX) and by removing oxidized fatty acids and phospholipids for disposing in the liver. Macrophages and resident cells in the artery wall internalize oxidized LDL and remnant particles via scavenger receptors, SRA1 and LOX-1, a process that can lead to foam cell formation and atherosclerosis. HDL can mitigate this process by extracting surplus cholesterol and phospholipids from lipid-laden cells for disposal in the liver (so-called RCT). This process involves binding of the lipid-poor HDL to ABCA1 transporter on the cell membrane which leads to efflux of free cholesterol from the cell to the HDL surface. Free cholesterol is then esterified by LCAT and sequestered in the core of HDL and its conversion to cholesterol ester-rich HDL-2. Thereafter, HDL-2 detaches from the cell and begins a journey to the liver, where it binds to the docking receptor SRB-1. SRB-1 accommodates unloading of the HDL’s lipid cargo and its subsequent detachment to repeat the cycle. As noted in the text, CKD results in the reduction (marked by an asterisk) in apoA-1, PON, GPX and LCAT and elevation (marked by a +) of ROS, and scavenger receptors. These disturbances contribute to the CKD-associated HDL deficiency and dysfunction. β-Chain of ATP synthase, which is the HDL endocytic receptor, binds apoA and lipid-poor HDL. Since due to LCAT deficiency and poor binding affinity to ABCA1, uremic HDL is lipid-poor, we speculate that its degradation via this pathway is increased in ESRD patients, thereby replacing the role of the kidney, which is normally the main route of apoA-1 degradation.

RCT is mediated by binding of HDL to ATP-binding cassette transporter type A1 (ABCA1) and ABCG1 (the gate keepers of cholesterol efflux) on the cell membrane [19,22]. Binding to the ABCA1 transporter initiates active transfer of free cholesterol and phospholipids to the surface of the lipid-poor discoid HDL [19], wherein free cholesterol is rapidly esterified by LCAT and transferred to the core of HDL. LCAT-mediated esterification of cholesterol is essential for maximal uptake of cholesterol by HDL. Binding of the mature HDL to ABCG-1 transporter causes further cholesterol enrichment of HDL [22]. In addition to the energy-dependent cholesterol uptake via these transporters, a small but significant amount of cellular free cholesterol is passively delivered to the circulating HDL via albumin which plays a partial role in RCT [23]. Once loaded with cholesterol ester, HDL travels to the liver where it binds to the HDL docking receptor, SRB-1. Binding to SRB-1 accommodates release of cholesterol ester content of HDL in the liver and hydrolysis of its triglyceride and phospholipid contents by hepatic lipase. After unloading its lipid cargo, HDL is released from the liver to repeat the cycle [24]. Unlike SRB1, the endocytic HDL receptor (β-chain of ATP synthase) mediates uptake and degradation apoA-1 and lipid-poor HDL particles in the liver [25].

goto top of outline HDL Abnormalities in CKD

Serum apoA-1 and HDL cholesterol concentrations are reduced, HDL triglyceride content is elevated, HDL maturation is impaired, proportion of lipid-poor pre-β-HDL is increased and antioxidant, anti-inflammatory and RCT capacity of HDL are greatly reduced in patients with advanced CKD [7,8,13,26]. Advanced CKD is associated with marked reduction in serum concentrations of apoA-I (the main protein constituent of HDL) and apoA-II [7,11,26]. The CKD-induced apoA-1 deficiency contributes to the overall reduction in plasma HDL in the ESRD population which appears to be due to its diminished production [27]. The primary reason for impaired maturation of cholesterol ester-poor pre-β-HDL to mature cholesterol ester-rich HDL in advanced CKD is LCAT deficiency. Serum LCAT activity and concentration are markedly reduced in ESRD patients [11,28], which is due to its diminished production by the liver in CKD [15,29,30]. In addition, hypoalbuminemia commonly seen in advanced CKD may, in part, contribute to reduced HDL cholesterol level. Studies conducted in experimental animals with CKD have revealed upregulation of ABCA-1 and ABCG-1 transporters in response to cellular cholesterol overload in the artery wall and remnant kidneys [31,32], thus excluding their deficiencies as a potential cause of impaired HDL maturation and RCT in CKD. It is of note that oxidative modification of HDL has been shown to limit the affinity of apoA-1 for binding to ABCA-1 transporters [33]. In fact, studies conducted in our laboratories have revealed evidence for marked oxidation of HDL in ESRD patients [11]. Therefore, CKD-induced oxidative modification of HDL can contribute to impaired RCT, defective HDL maturation and accumulation of lipids in the remnant kidney and artery wall in this population.

Clinical studies have found no significant difference in serum CETP concentration or activity between hemodialysis patients and normal control individuals [34,35]. However, data on the effect of peritoneal dialysis on serum CETP are lacking. Hepatic expression and serum concentration of CETP are elevated in patients with heavy proteinuria [36,37]. Given the significant losses of proteins with peritoneal dialysis procedure, we speculate that serum CETP may be elevated in patients undergoing peritoneal dialysis.

Reduction in HDL cholesterol in advanced CKD is coupled with elevated HDL triglyceride contents. This is primarily due to deficiency in hepatic triglyceride lipase, which is a well documented consequence chronic renal failure [38,39,40].

Hepatic SRB-1 is the final destination in HDL-mediated RCT. The effect of ESRD on hepatic expression of HDL docking receptor (SRB-1) and endocytic receptor (β-chain subunit of mitochondrial ATP synthase) in human is not known. However, studies conducted in our laboratory demonstrated no significant difference in the liver tissue SRB-1 abundance in rats with CKD induced by subtotal nephrectomy [27,41]. In contrast SRB-1 abundance was significantly reduced in animals with experimental nephrotic syndrome [40]. Based on these observations, we speculate that hepatic SRB-1 may be unchanged in hemodialysis patients and reduced in peritoneal dialysis patients who generally experience significant protein losses in peritoneal dialysate effluent. If true, downregulation of SRB-1 can further compromise HDL-mediated RCT in such patients.

As noted above, HDL possesses potent antioxidant and anti-inflammatory properties which are critical in protection against foam cell formation by preventing oxidation of LDL and activation of leukocyte and endothelial cells. In a recent study, we found marked reductions in HDL antioxidant capacity in ESRD patients maintained on hemodialysis [11]. This was associated with significant reduction in paraoxonase, and glutathione peroxidase, the HDL-associated antioxidant enzymes [11]. In a subsequent study, we found marked reduction in HDL anti-inflammatory activity in ESRD patients [12]. The reduction in HDL antioxidant and anti-inflammatory properties in ESRD is most likely due to the prevailing oxidative stress and inflammation as shown in other conditions [18]. Conversely, reduction in antioxidant and anti-inflammatory properties of HDL in ESRD can intensify the inciting oxidative stress and inflammation.

goto top of outline Adverse Impact of CKD-Associated HDL Abnormalities

The CKD-associated HDL deficiency and dysfunction have numerous adverse consequences: (a) CKD-induced reduction in apoA-1, paraoxonase and glutathione peroxidase limits the ability of HDL to prevent or reverse oxidation of LDL and phospholipids. This, in turn, promotes influx of oxidized LDL in macrophages and resident cells in the artery wall and facilitates foam cell formation and atherosclerosis. (b) The CKD-associated oxidative modification of HDL [11] diminishes HDL binding affinity for ABCA-1 transporter which limits RCT. (c) LCAT and apoA-1 deficiencies and hypoalbuminemia accelerate atherosclerosis by limiting RCT. (d) The CKD-induced deficiency of HDL, which is the most potent plasma antioxidant factor, contributes to the severity of the prevailing oxidative stress and its adverse outcomes in this population. (e) As a potent anti-inflammatory component of the plasma, the CKD-induced HDL deficiency and dysfunction contribute to the prevailing inflammatory state and its adverse outcomes in CKD. (f) Since HDL avidly binds and removes endotoxin, its deficiency may contribute to the presence of endotoxemia [42,43] and inflammation in ESRD patients and their poor outcome with microbial infections. (g) Given the antithrombotic effect of normal HDL, its deficiency and dysfunction may contribute to blood access thrombosis.

 

goto top of outline Disorders of Triglyceride-Rich Lipoprotein Metabolism in CKD

goto top of outline Triglyceride-Rich Lipoprotein Metabolism

Pathways of VLDL and chylomicron metabolism are depicted in figures 2 and 3. VLDL and chylomicrons serve as vehicles for delivery of lipid fuel to the muscle for production of energy and to adipose tissue for storage of energy. This process is mediated by endothelium-bound lipoprotein lipase in the capillaries that perfuse skeletal muscle, adipose tissue and myocardium, wherein this enzyme catalyzes hydrolysis of triglycerides in VLDL and chylomicrons. This results in the release of over 70% of the fatty acid contents of these particles for uptake by the adjacent adipocytes and myocytes and formation of partially lipid-depleted VLDL (IDL) and chylomicron remnants. Chylomicron remnants and a small fraction of IDL are normally cleared by the liver via LDL receptor-related protein (LRP) [44]. Normally, the great majority of IDL particles are converted to LDL. Conversion of IDL to LDL requires cholesterol enrichment of IDL and removal of essentially all of its remaining triglyceride contents. This process involves CETP-mediated exchange of cholesterol esters for triglycerides between HDL and IDL and subsequent clearance of the residual triglyceride content of IDL by hepatic lipase. The cholesterol ester-rich and triglyceride-depleted LDL produced in this manner is then readily cleared by LDL receptor. In addition to lipolytic pathway, VLDL is directly cleared by adipocytes and myocytes via VLDL receptor which is abundantly expressed in the muscle and adipose tissues [45].

FIG02
Fig. 2. Pathways of VLDL metabolism. Nascent VLDL is produced and released in the circulation by the liver by packaging lipid droplets containing triglycerides (TG), cholesterol ester (CE) and phospholipids in the core of ApoB100. In the circulation, nascent VLDL acquires ApoE and ApoC from HDL-2 to become mature VLDL. In the capillaries perfusing muscles and adipose tissues, VLDL undergoes lipolysis of its TG contents by lipoprotein lipase (LPL), leading to release of 70% of its fatty acid (FA) contents, most of which are taken up by the adjacent adipocytes for energy storage and myocytes for energy production. This leads to formation and release of the VLDL remnant, commonly known as IDL, which undergoes further lipolysis by hepatic lipase and CE enrichment by cholesterol ester transfer protein (CETP) to become LDL. In addition, a small fraction of IDL is removed by the liver via a multifunctional receptor known as LRP. The bulk of IDL is converted to LDL, a process that involves cholesterol enrichment and TG depletion. This process is mediated by the actions of CETP and hepatic lipase. The CE-rich, TG-depleted LDL formed in this manner is then cleared by LDL receptor. In addition to the lipolytic pathway, VLDL is removed in its entirety via VLDL receptor (VLDLr) which is abundantly expressed by adipocytes and myocytes. CKD results in downregulation (marked with an asterisk) of LPL, hepatic lipase, LRP and VLDLr, which collectively account for elevation of serum triglycerides, VLDL, accumulation of IDL and TG enrichment of LDL on the one hand, and diminished availability of lipid fuel for skeletal muscle and storage for adipose tissue in patients with CKD on the other.

FIG03
Fig. 3. Pathway of chylomicron metabolism. Chylomicrons are the vehicle for delivery of dietary lipid fuel to muscle for energy production and to adipose tissue for energy storage. Nascent chylomicron is produced by packaging lipid droplets containing triglycerides, cholesterol esters and phospholipids in ApoB48. After receiving apoE and apoC from HDL-2, chylomicrons undergo lipolysis by lipoprotein lipase (LPL) in the muscle and adipose tissues leading to formation of chylomicron remnants which are normally cleared by the liver via LRP. CKD results in downregulation (marked with an asterisk) of LPL and LRP, which collectively contribute to impaired clearance of chylomicrons and accumulation of their atherogenic remnants in CKD.

goto top of outline Disorders of Triglyceride-Rich Lipoprotein Metabolism in CKD

ESRD results in elevation of serum triglycerides and VLDL concentrations, which is solely due to impaired clearance of VLDL and chylomicrons and accumulation of their oxidation-prone atherogenic remnants [7,9,20]. These abnormalities are due to the CKD-induced downregulation of lipoprotein lipase and VLDL receptor in the adipose tissue, skeletal muscle and cardiac muscle and hepatic lipase and LRP in the liver as well as increased plasma apoC-III (a potent inhibitor of lipoprotein lipase)/apoC-II (activator of lipoprotein lipase) ratio [7,9].

Nearly all critical steps in metabolism/clearance of VLDL and chylomicrons and their remnants are severely impaired in CKD. For instance, CKD results in marked reduction in lipoprotein lipase activity in humans (as evidenced by diminished post-heparin lipolytic activity) and of lipoprotein lipase expression and activity in experimental animals [7,20,46]. Lipoprotein lipase deficiency in CKD is compounded by increased apoCIII and reduced apoCII contents of VLDL and chylomicrons, which significantly lowers their ability to activate this enzyme. Moreover, reduced apoE contents of VLDL and chylomicrons limit their ability to bind to the capillary endothelium which is critical for their interaction with lipoprotein lipase and with binding of VLDL to VLDL receptor. Animal studies have demonstrated the contribution of CKD-induced hyperparathyroidism to the pathogenesis of lipoprotein lipase deficiency [47] confirming the observations made in ESRD patients [48]. In addition, impaired HDL maturation, insulin resistance, reduced physical activity and diminished thyroxin to tri-iodothyronin conversion, which are common features of ESRD, contribute to diminished production and impaired activity of lipoprotein lipase. Finally, recurrent heparinization in the course of hemodialysis procedure is thought to further contribute to lipoprotein lipase depletion in ESRD patients by promoting release and degradation of the tissue-bound stores of this molecule [7]. In addition to causing lipoprotein lipase deficiency, CKD results in significant downregulation of LRP in the liver [49]. This phenomenon can contribute to accumulation of the atherogenic chylomicron remnants and IDL in patients with CKD.

As noted earlier, hepatic lipase plays a crucial part in conversion of IDL to LDL. CKD has been shown to significantly reduce expression and activity of this important enzyme as well [38,39,40]. The CKD-induced hepatic lipase deficiency can, therefore, contribute to accumulation of IDL, triglyceride-enrichment of LDL and HDL and hyper-triglyceridemia in this population. Likewise, hepatic lipase deficiency can account for triglyceride enrichment of HDL in CKD. Finally, CKD results in marked downregulation of VLDL receptor in the skeletal muscle, heart and adipose tissue [50,51] which contributes to impaired clearance of VLDL, elevation of serum VLDL and hypertriglyceridemia in CKD patients.

Acyl-CoA:diglycerol acyl-transferase (DGAT) catalyzes conversion of diglyceride to triglyceride and as such represents the final step in triglyceride synthesis. Advanced CKD has been shown to significantly reduce hepatic DGAT expression and activity in experimental animals [52]. Based on these observations, increased production may be excluded as a cause of hypertriglyceridemia in advanced CKD or ESRD. However, this may not be true in CKD patients with heavy proteinuria or ESRD patients maintained on peritoneal dialysis. This supposition is based on the observation that heavy proteinuria significantly increases hepatic DGAT abundance and activity [53]. If true, more severe hypertriglyceridemia seen in such patients may be due to a combination of increased production and reduced clearance of triglyceride.

goto top of outline Impact of CKD-Associated Defects on VLDL and Chylomicron Metabolism

Impaired clearance of triglyceride-rich lipoproteins and accumulation of their oxidation-prone, atherogenic remnants in patients with advanced CKD has major adverse consequences. (a) By limiting uptake of lipid fuel in the adipocytes and myocytes, downregulation of lipoprotein lipase and VLDL receptor contributes to development of cachexia and diminished exercise capacity in ESRD patients. (b) Accumulation of oxidation-prone IDL, chylomicron remnants, and triglyceride-containing small dense LDL promotes accelerated atherosclerosis. (c) Binding of oxidized LDL and phospholipids to their receptors on immune cells triggers the release of proinflammatory cytokines and chemokines which, in turn, contribute to development and intensification of CKD-associated inflammation. (d) The circulating oxidized lipoprotein remnants disseminate and sustain the flames of oxidative stress throughout the body by initiating lipid peroxidation chain reaction.

In this context, oxidized lipids and lipoproteins are both the cause and consequence of oxidative stress.

In conclusion, CKD results in profound dysregulation of lipid metabolism which in turn contributes to the pathogenesis of cardiovascular disease and numerous other adverse consequences in this population.


 goto top of outline References
  1. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
  2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
  3. Vaziri ND: Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 2004;24:469–473.
  4. Kim HJ, Vaziri ND: Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298:F662–F671.
  5. McCullough PA: Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725–728.
  6. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329–337.
  7. Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006;290:262–272.
  8. Vaziri ND: Lipotoxicity and impaired HDL-mediated reverse cholesterol/lipid transport in chronic kidney disease. J Renal Nutr 2010;20:S35–S43.
  9. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P: Dialysis modalities and dyslipidemia. Kidney Int Suppl 2003;84:S110–S112.
  10. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852–862.
  11. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 2009;153:77–85.
  12. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009;76:437–444.
  13. Vaziri ND, Navab M, Fogelman AM: HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010;6:287–296.
  14. Vaziri ND, Liang KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979–1985.
  15. Vaziri ND, Sato T, Liang K: Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 2003;63:1756–1763.
  16. Moradi H, Ganji S, Kamanna VJ, Pahl MV, Vaziri ND: Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease – response to antioxidant therapy. Clin Nephrol 2010;74:273–281.
  17. Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090–3100.
  18. Ansell BJ, Navab M, Hama S, et al: Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751–2756.
  19. Fielding CJ, Fielding PE: Cellular cholesterol efflux. Biochim Biophys Acta 2001;1533:175–189.
  20. Kaysen GA: Hyperlipidemia in chronic kidney disease. Int J Artif Organs 2007;30:987–992.
  21. Barter PJ, et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109–2122.
  22. Oram JF, Vaughan AM: ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006;99:1031–1043.
  23. Zhao Y, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 1996;35:7174–7180.
  24. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518–520.
  25. Fabre AC, Vantourout P, Champagne E, Tercé F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO: Cell surface adenylate kinase activity regulates the F (1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 2006;63:2829–2837.
  26. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573–592.
  27. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999;14:1462–1466.
  28. Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41:1653–1661.
  29. Liang K, Kim C, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005;288:F539–F544.
  30. Vaziri ND, Liang K, Parks JS: Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 2001;59:2192–2196.
  31. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND: Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol 2009;30:147–154.
  32. Kim HJ, Moradi H, Vaziri ND: Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol 2009;296:F1297–F1306.
  33. Shao B, Oda MN, Oram JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006;21:322–328.
  34. Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H: Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis 2001;38:70–76.
  35. Pahl MV, Ni Z, Sepassi L, Vaziri ND: Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant 2009;24:2541–2546.
  36. De Sain-van der Velden MG, Rabelink TJ, Reijngoud DJ, Gadellaa MM, Voorbij HA, Stellaard F, Kaysen GA: Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone. Kidney Int 1998;54:530–535.
  37. Vaziri ND: Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int 2003;63:1964–1976.
  38. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG: Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996;97:2167–2173.
  39. Liang K, Vaziri ND: Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 1997;51:1933–1937.
  40. Sato T, Liang K, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int 2003;64:1780–1786.
  41. Liang K, Vaziri ND: Downregulation of hepatic high-density lipoprotein receptor, SRB-1 in nephrotic syndrome. Kidney Int 1999;56:621–626.
  42. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, Li PK: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3:431–436.
  43. Gonçalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, Fuerbringer R, Sauthier SM, Riella MC: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006;21:2788–2794.
  44. Herz J, Strickland DK: LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779–784.
  45. Takahashi S, Warabayasi Y, Nakai T, Sakai J, Yamamoto T: Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992;89:9252–9256.
  46. Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996;50:1928–1935.
  47. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 1997;273:F925–F930.
  48. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990;37:854–858.
  49. Kim C, Vaziri ND: Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 2005;67:1028–1032.
  50. Vaziri ND, Liang K: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997;51:913–919.
  51. Liang K, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998;53:626–630.
  52. Vaziri ND, Dang B, Zhan CD, Liang K: Downregulation of hepatic Acyl-CoA:di glycerol acyltransferase (DGAT) in chronic renal failure. Am J Physiol Renal Physiol 2004;287:F90–F94.
  53. Vaziri ND, Kim CH, Phan D, Kim S, Liang K: Upregulation of acyl-CoA:diacylglycerol acyltransferase (DGAT) expression in nephrotic syndrome. Kidney Int 2004;66:262–267.

 goto top of outline Author Contacts

N.D. Vaziri, MD, MACP
University of California, Irvine Medical Center
Division of Nephrology and Hypertension
The City Tower, 4th floor, Orange CA 92868 (USA)
Tel. +1 714 456 5142, Fax +1 714 456 6034, E-Mail ndvaziri@uci.edu


 goto top of outline Article Information

Published online: January 10, 2011
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 0, Number of References : 53


 goto top of outline Publication Details

Blood Purification

Vol. 31, No. 1-3, Year 2011 (Cover Date: January 2011)

Journal Editor: Ronco C. (Vicenza)
ISSN: 0253-5068 (Print), eISSN: 1421-9735 (Online)

For additional information: http://www.karger.com/BPU


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Cardiovascular disease is the major cause of death in patients with chronic kidney disease (CKD). Cardiovascular disease and many other complications of CKD are mediated by oxidative stress, inflammation, and dyslipidemia. This review provides a concise overview of the nature and mechanisms of CKD-induced lipid disorders and their adverse consequences. Lipid abnormalities in end-stage renal disease are characterized by: (a) reduced serum apoA-1 and high-density lipoprotein (HDL) concentrations, impaired HDL maturation and defective HDL antioxidant, anti-inflammatory and reverse cholesterol transport properties; (b) impaired clearance of very low-density lipoprotein and chylomicrons by the muscle and adipose tissue and of their remnants by the liver leading to hypertriglyceridemia, accumulation of intermediate-density lipoprotein and chylomicron remnants, and (c) oxidative modification of LDL and lipoprotein remnants favored by their structural abnormalities, oxidative stress, and impaired HDL antioxidant activity. Together these abnormalities result in: (a) uptake of oxidized LDL and remnant particles by macrophages and resident cells in the artery wall which along with impaired HDL-mediated reverse cholesterol transport causes foam cell formation and atherosclerosis, (b) production of inflammatory mediators and reactive oxygen species by leukocytes and macrophages in response to stimulation by oxidized LDL and phospholipids leading to intensification of oxidative stress and inflammation, (c) dissemination of oxidative stress by circulating oxidized lipids and lipoproteins via lipid peroxidation chain reaction, (d) heightened injurious effects of oxidative stress and inflammation due to diminished antioxidant, anti-inflammatory and antithrombotic activities of HDL, and finally (e) impaired ability of very low-density lipoprotein and chylomicron to deliver lipid fuel to muscle and adipose tissue contributing to muscle weakness and cachexia which commonly occur in end-stage renal disease patients.



 goto top of outline Author Contacts

N.D. Vaziri, MD, MACP
University of California, Irvine Medical Center
Division of Nephrology and Hypertension
The City Tower, 4th floor, Orange CA 92868 (USA)
Tel. +1 714 456 5142, Fax +1 714 456 6034, E-Mail ndvaziri@uci.edu


 goto top of outline Article Information

Published online: January 10, 2011
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 0, Number of References : 53


 goto top of outline Publication Details

Blood Purification

Vol. 31, No. 1-3, Year 2011 (Cover Date: January 2011)

Journal Editor: Ronco C. (Vicenza)
ISSN: 0253-5068 (Print), eISSN: 1421-9735 (Online)

For additional information: http://www.karger.com/BPU


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
  2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
  3. Vaziri ND: Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 2004;24:469–473.
  4. Kim HJ, Vaziri ND: Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298:F662–F671.
  5. McCullough PA: Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725–728.
  6. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329–337.
  7. Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006;290:262–272.
  8. Vaziri ND: Lipotoxicity and impaired HDL-mediated reverse cholesterol/lipid transport in chronic kidney disease. J Renal Nutr 2010;20:S35–S43.
  9. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P: Dialysis modalities and dyslipidemia. Kidney Int Suppl 2003;84:S110–S112.
  10. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852–862.
  11. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 2009;153:77–85.
  12. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009;76:437–444.
  13. Vaziri ND, Navab M, Fogelman AM: HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010;6:287–296.
  14. Vaziri ND, Liang KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979–1985.
  15. Vaziri ND, Sato T, Liang K: Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 2003;63:1756–1763.
  16. Moradi H, Ganji S, Kamanna VJ, Pahl MV, Vaziri ND: Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease – response to antioxidant therapy. Clin Nephrol 2010;74:273–281.
  17. Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090–3100.
  18. Ansell BJ, Navab M, Hama S, et al: Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751–2756.
  19. Fielding CJ, Fielding PE: Cellular cholesterol efflux. Biochim Biophys Acta 2001;1533:175–189.
  20. Kaysen GA: Hyperlipidemia in chronic kidney disease. Int J Artif Organs 2007;30:987–992.
  21. Barter PJ, et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109–2122.
  22. Oram JF, Vaughan AM: ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006;99:1031–1043.
  23. Zhao Y, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 1996;35:7174–7180.
  24. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518–520.
  25. Fabre AC, Vantourout P, Champagne E, Tercé F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO: Cell surface adenylate kinase activity regulates the F (1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 2006;63:2829–2837.
  26. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573–592.
  27. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999;14:1462–1466.
  28. Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41:1653–1661.
  29. Liang K, Kim C, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005;288:F539–F544.
  30. Vaziri ND, Liang K, Parks JS: Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 2001;59:2192–2196.
  31. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND: Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol 2009;30:147–154.
  32. Kim HJ, Moradi H, Vaziri ND: Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol 2009;296:F1297–F1306.
  33. Shao B, Oda MN, Oram JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006;21:322–328.
  34. Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H: Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis 2001;38:70–76.
  35. Pahl MV, Ni Z, Sepassi L, Vaziri ND: Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant 2009;24:2541–2546.
  36. De Sain-van der Velden MG, Rabelink TJ, Reijngoud DJ, Gadellaa MM, Voorbij HA, Stellaard F, Kaysen GA: Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone. Kidney Int 1998;54:530–535.
  37. Vaziri ND: Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int 2003;63:1964–1976.
  38. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG: Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996;97:2167–2173.
  39. Liang K, Vaziri ND: Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 1997;51:1933–1937.
  40. Sato T, Liang K, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int 2003;64:1780–1786.
  41. Liang K, Vaziri ND: Downregulation of hepatic high-density lipoprotein receptor, SRB-1 in nephrotic syndrome. Kidney Int 1999;56:621–626.
  42. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, Li PK: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3:431–436.
  43. Gonçalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, Fuerbringer R, Sauthier SM, Riella MC: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006;21:2788–2794.
  44. Herz J, Strickland DK: LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779–784.
  45. Takahashi S, Warabayasi Y, Nakai T, Sakai J, Yamamoto T: Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992;89:9252–9256.
  46. Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996;50:1928–1935.
  47. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 1997;273:F925–F930.
  48. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990;37:854–858.
  49. Kim C, Vaziri ND: Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 2005;67:1028–1032.
  50. Vaziri ND, Liang K: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997;51:913–919.
  51. Liang K, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998;53:626–630.
  52. Vaziri ND, Dang B, Zhan CD, Liang K: Downregulation of hepatic Acyl-CoA:di glycerol acyltransferase (DGAT) in chronic renal failure. Am J Physiol Renal Physiol 2004;287:F90–F94.
  53. Vaziri ND, Kim CH, Phan D, Kim S, Liang K: Upregulation of acyl-CoA:diacylglycerol acyltransferase (DGAT) expression in nephrotic syndrome. Kidney Int 2004;66:262–267.